Screener
ArriVent BioPharma, Inc. AVBP Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Total operating expenses | 46,111 | 66,772 |
| Operating loss | (46,111) | (66,772) |
| Interest and investment income | 2,791 | 2,385 |
| Net loss | (43,320) | (64,387) |
| Unrealized gain (loss) on marketable securities | (284) | 194 |
| Total other comprehensive gain (loss) | (284) | 194 |
| Total comprehensive loss | $(43,604) | $(64,193) |
| Share information: |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s net income?
- ArriVent BioPharma, Inc. (AVBP) reported net income of -$43.32M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s net income changed year-over-year?
- ArriVent BioPharma, Inc.'s net income increased by 32.7% year-over-year, from -$64.39M to -$43.32M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s net income?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s net income has grown at a 54.9% compound annual growth rate (CAGR), from -$69.33M to -$166.31M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about ArriVent BioPharma, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude